Skip to main
MIRM

MIRM Stock Forecast & Price Target

MIRM Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 69%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Mirum Pharmaceuticals is well-positioned for continued growth and success in the rare and orphan disease space, with its main product, Livmarli, showing strong momentum in sales and continued expansion into new indications. Additionally, the company has a robust pipeline of potential treatments for various liver diseases, with multiple near-term catalysts expected. Mirum's solid financials, including its high cash reserves and expected cash flow positivity in 2027, make it a promising investment opportunity for investors with a long-term outlook. However, risks exist, including potential delays in drug approvals and potential dilution. Despite these risks, Mirum is expected to continue its trajectory of success in the rare disease market.

Bears say

Mirum Pharmaceuticals is expected to face a challenging road to success, as its main product Livmarli is only approved for one indication and its other products are still in the clinical trial phase. The company's recent quarter was overshadowed by the disappointing feedback from the FDA regarding its potential submission for volixibat in PSC. Additionally, while the company's acquisition of Chenodal and Cholbam may expand its pipeline, it is not a guarantee for success in the highly competitive biopharmaceutical industry.

MIRM has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 69% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mirum Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mirum Pharmaceuticals Inc (MIRM) Forecast

Analysts have given MIRM a Buy based on their latest research and market trends.

According to 13 analysts, MIRM has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $135.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $135.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mirum Pharmaceuticals Inc (MIRM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.